• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CCR5受体细胞外部分对RANTES的识别。

Recognition of RANTES by extracellular parts of the CCR5 receptor.

作者信息

Duma Luminita, Häussinger Daniel, Rogowski Marco, Lusso Paolo, Grzesiek Stephan

机构信息

Division of Structural Biology, Biozentrum, University of Basel, Klingelbergstr. 70, Basel, Switzerland.

出版信息

J Mol Biol. 2007 Jan 26;365(4):1063-75. doi: 10.1016/j.jmb.2006.10.040. Epub 2006 Oct 17.

DOI:10.1016/j.jmb.2006.10.040
PMID:17101151
Abstract

The chemokine RANTES (regulated upon activation, normal T-cell expressed and secreted) is a natural ligand of CCR5, one of the major HIV-1 coreceptors. It is secreted as part of the immune response to human immunodeficiency virus 1 (HIV-1) and inhibits infection by CCR5-dependent (R5) HIV-1 isolates. We have investigated the interaction of RANTES with several peptides derived from the extracellular domains of CCR5 by heteronuclear NMR spectroscopy in aqueous solution. We show that a peptide comprising the first 25 amino acid residues of the CCR5 N-terminal domain and sulfated at the Y10 and Y14 side-chains binds with micromolar affinity exclusively to the monomeric form of RANTES. In contrast to the tight binding of the sulfated peptide, the affinity of the same peptide in non-sulfated form was reduced by more than two orders of magnitude. Peptides derived from the CCR5 extracellular loops ECL1, ECL2 and ECL3 showed only very moderate and mostly non-specific binding. Chemical shift mapping of the interaction of the sulfated N-terminal peptide reveals a contiguous binding surface on RANTES, which comprises amino acid residues of the first beta-strand, the N-loop, the fourth beta-strand and the turns around residues 30 and 40. This binding surface largely overlaps with the dimer interface and is strongly positively charged, providing a rationale for the exclusive binding of the monomer to the peptide and the requirement of the negative sulfate groups at the Y10 and Y14 side-chains. The binding surface also largely overlaps with the segments that were identified previously as crucial for HIV blockade by peptide scanning and mutagenesis studies. These data offer new insights into the structure-function relation of the RANTES-CCR5 interaction and may be helpful for the design of novel HIV-1 inhibitors.

摘要

趋化因子RANTES(活化时受调控、正常T细胞表达和分泌)是主要的HIV-1共受体之一CCR5的天然配体。它作为对人类免疫缺陷病毒1(HIV-1)免疫反应的一部分被分泌,并抑制CCR5依赖性(R5)HIV-1分离株的感染。我们通过水溶液中的异核核磁共振光谱研究了RANTES与源自CCR5细胞外结构域的几种肽的相互作用。我们发现,一种包含CCR5 N端结构域前25个氨基酸残基且在Y10和Y14侧链处硫酸化的肽,以微摩尔亲和力仅与RANTES的单体形式结合。与硫酸化肽的紧密结合相反,相同肽的非硫酸化形式的亲和力降低了两个多数量级。源自CCR5细胞外环ECL1、ECL2和ECL3的肽仅表现出非常适度且大多是非特异性的结合。硫酸化N端肽相互作用的化学位移图谱揭示了RANTES上一个连续的结合表面,该表面包含第一条β链、N环、第四条β链以及残基30和40周围的转角处的氨基酸残基。这个结合表面在很大程度上与二聚体界面重叠,且带强正电荷,这为单体与肽的特异性结合以及Y10和Y14侧链上负硫酸基团的必要性提供了理论依据。该结合表面也在很大程度上与先前通过肽扫描和诱变研究确定的对HIV阻断至关重要的片段重叠。这些数据为RANTES-CCR5相互作用的结构-功能关系提供了新的见解,可能有助于新型HIV-1抑制剂的设计。

相似文献

1
Recognition of RANTES by extracellular parts of the CCR5 receptor.CCR5受体细胞外部分对RANTES的识别。
J Mol Biol. 2007 Jan 26;365(4):1063-75. doi: 10.1016/j.jmb.2006.10.040. Epub 2006 Oct 17.
2
Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.生理和病毒趋化因子以及HIV-1包膜糖蛋白与CCR5结合的分子解剖学:RANTES、MIP-1α和vMIP-II结合的一级结构要求差异
J Mol Biol. 2001 Nov 9;313(5):1181-93. doi: 10.1006/jmbi.2001.5086.
3
Antiviral chemokines: intracellular life of recombinant C-C chemokine RANTES.抗病毒趋化因子:重组C-C趋化因子RANTES的细胞内生命历程
J Hum Virol. 1999 Sep-Oct;2(5):270-82.
4
Electrostatic modeling of peptides derived from the V3-loop of HIV-1 gp120: implications of the interaction with chemokine receptor CCR5.源自HIV-1 gp120 V3环的肽段的静电建模:与趋化因子受体CCR5相互作用的意义
Int J Mol Med. 2007 Mar;19(3):343-51.
5
Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES.RANTES中CCR5识别及HIV-1阻断的结构决定因素
Nat Struct Biol. 2001 Jul;8(7):611-5. doi: 10.1038/89653.
6
NMR evidence of charge-dependent interaction between various PND V3 and CCR5 N-terminal peptides.
Biopolymers. 2009;92(2):94-109. doi: 10.1002/bip.21127.
7
Large-scale expression and purification of the major HIV-1 coreceptor CCR5 and characterization of its interaction with RANTES.主要HIV-1共受体CCR5的大规模表达与纯化及其与RANTES相互作用的表征
Protein Expr Purif. 2008 Oct;61(2):155-62. doi: 10.1016/j.pep.2008.06.001. Epub 2008 Jun 8.
8
NMR mapping of RANTES surfaces interacting with CCR5 using linked extracellular domains.使用连接的细胞外结构域对与 CCR5 相互作用的 RANTES 表面进行 NMR 作图。
FEBS J. 2013 May;280(9):2068-84. doi: 10.1111/febs.12230. Epub 2013 Apr 2.
9
Total chemical synthesis and high-resolution crystal structure of the potent anti-HIV protein AOP-RANTES.强效抗HIV蛋白AOP-RANTES的全化学合成及高分辨率晶体结构
Chem Biol. 1999 Jan;6(1):43-51. doi: 10.1016/S1074-5521(99)80019-2.
10
Peptide T blocks GP120/CCR5 chemokine receptor-mediated chemotaxis.肽T可阻断GP120/CCR5趋化因子受体介导的趋化作用。
Clin Immunol. 1999 Nov;93(2):124-31. doi: 10.1006/clim.1999.4771.

引用本文的文献

1
Identification and interaction mechanism of novel small molecule antagonists targeting CC chemokine receptor 1/3/5 for treatment of non-small cell lung cancer.靶向CC趋化因子受体1/3/5治疗非小细胞肺癌的新型小分子拮抗剂的鉴定及其相互作用机制
Mol Divers. 2024 Nov 22. doi: 10.1007/s11030-024-11025-1.
2
Sulfated CXCR3 Peptide Trap Use as a Promising Therapeutic Approach for Age-Related Macular Degeneration.硫酸化CXCR3肽阱作为年龄相关性黄斑变性的一种有前景的治疗方法
Biomedicines. 2024 Jan 22;12(1):241. doi: 10.3390/biomedicines12010241.
3
Antiretrovirals to CCR5 CRISPR/Cas9 gene editing - A paradigm shift chasing an HIV cure.
抗逆转录病毒药物对 CCR5 CRISPR/Cas9 基因编辑——追求 HIV 治愈的范式转变。
Clin Immunol. 2023 Oct;255:109741. doi: 10.1016/j.clim.2023.109741. Epub 2023 Aug 21.
4
A novel small-molecular CCR5 antagonist promotes neural repair after stroke.一种新型小分子 CCR5 拮抗剂促进中风后的神经修复。
Acta Pharmacol Sin. 2023 Oct;44(10):1935-1947. doi: 10.1038/s41401-023-01100-y. Epub 2023 May 17.
5
Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.将CCR5作为HIV-1治疗策略的一个组成部分进行靶向治疗。
Front Immunol. 2022 Jan 20;12:816515. doi: 10.3389/fimmu.2021.816515. eCollection 2021.
6
Structural basis of the activation of the CC chemokine receptor 5 by a chemokine agonist.CC 趋化因子受体 5 激动剂激活的结构基础。
Sci Adv. 2021 Jun 16;7(25). doi: 10.1126/sciadv.abg8685. Print 2021 Jun.
7
N-terminal Backbone Pairing Shifts in CCL5-AAA Dimer Interface: Structural Significance of the FAY Sequence.CCL5-AAA 二聚体界面中的 N 端骨架配对移位:FAY 序列的结构意义。
Int J Mol Sci. 2020 Mar 1;21(5):1689. doi: 10.3390/ijms21051689.
8
Regulating G protein-coupled receptors by topological inversion.通过拓扑反转调节 G 蛋白偶联受体。
Elife. 2019 Mar 5;8:e40234. doi: 10.7554/eLife.40234.
9
Evaluation and extension of the two-site, two-step model for binding and activation of the chemokine receptor CCR1.评价和扩展趋化因子受体 CCR1 的结合和激活的两点两步模型。
J Biol Chem. 2019 Mar 8;294(10):3464-3475. doi: 10.1074/jbc.RA118.006535. Epub 2018 Dec 19.
10
The solution structure of monomeric CCL5 in complex with a doubly sulfated N-terminal segment of CCR5.单体 CCL5 与 CCR5 的双硫酸化 N 端片段复合物的溶液结构。
FEBS J. 2018 Jun;285(11):1988-2003. doi: 10.1111/febs.14460. Epub 2018 Apr 20.